This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Mailbag 2008 Review

I went back and re-read all the Biotech Mailbag columns written in 2008 and was amazed to see that I wrote about 65 different biotech companies this year, many of them several times.

My thanks and gratitude go out to all the readers who emailed questions and comments this year. The Biotech Mailbag would be rather anemic if it weren't for your passion and curiosity.

The Mailbag in 2008 had its share of hits and misses. I managed to please a lot of you; others couldn't stand some of the things I wrote and let me know it in no uncertain terms.

Elan (ELN) received more play in the Mailbag this year than any other stock, mainly due to my ongoing (and quite skeptical) coverage of the company's experimental Alzheimer's disease drug bapineuzumab. The "Elanians" -- followers and fans of Elan -- are a vocal bunch, for sure.

I made some stock calls this year in the Mailbag. Some worked, others didn't.

Readers and I had a multi-Mailbag debate over the approvability of Vanda Pharmaceuticals' (VNDA - Get Report) schizophrenia drug iloperidone. Many readers were optimistic about FDA approval. I wasn't, mainly because iloperidone seemed like a "me-too" drug with poorer safety and worse side effects. In the end, the FDA chose not to approve the drug.

Earlier in the year, I highlighted Middlebrook Pharmaceuticals (MBRK) because I thought an acquisition of the company would double the stock price. That takeout never happened. Bad call.

I also thought that Cardiome (CRME) and its partner Astellas would be successful in getting their anti-arrhythmia drug Kynapid approved by the FDA, even through a year's worth of regulatory delays. To date, Kynapid is still not approved.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
AMGN $163.95 0.00%
DCTH $0.45 0.00%
GNVC $1.71 0.00%
GILD $107.78 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs